AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Stegsita-M50 Tablet

Prescription Icon
Prescription Required

Marketer

Metalis Lifesciences Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Stegsita-M50 Tablet

Combiflex-DM50 tablets combine two medications to manage elevated blood glucose in type 2 diabetes patients. This helps prevent serious diabetic complications like renal failure and vision loss, potentially lowering heart attack and stroke risk. Combiflex-DM50 may be used alone or with other antidiabetic drugs, and is most effective with diet and exercise. Dosage is tailored to individual health, blood sugar readings, and other medications. Taking it with food minimizes stomach upset. Consistent daily dosing at the same time maximizes benefits; discontinuation should only occur under physician guidance. Adherence to the prescribed diet and exercise plan is crucial. Lifestyle significantly impacts diabetes control. Common side effects include nausea, diarrhea, vomiting, indigestion, headache, and pharyngitis. Hypoglycemia is possible with concurrent insulin or sulfonylurea use; proper recognition and management are essential. This medication isn't for everyone. Inform your doctor of prior kidney, liver, or heart disease, pancreatic issues, or excessive alcohol consumption before use. Pregnant or lactating women should consult their physician. Interactions with other medications are possible; disclose all medications to ensure safety. Alcohol should be limited due to its hypoglycemic effects. Your physician will monitor kidney function and blood sugar levels throughout treatment.

Uses of Stegsita-M50 Tablet

Managing Type 2 Diabetes

Major Benefits of Stegsita-M50 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and timeframe. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Stegsita-M50 Tablet should be administered with a meal.

Common Side effects of Stegsita-M50 Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Stegsita-M50 Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. It's recommended to take Stegsita-M50 Tablet with a meal.

How Stegsita-M50 Tablet works:

Stegsita-M50 tablets contain sitagliptin and metformin, working synergistically to manage blood glucose. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and reduces hepatic glucose output. Metformin, a biguanide, decreases liver glucose production, slows intestinal glucose absorption, and boosts insulin sensitivity. This dual action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Consuming alcohol alongside Stegsita-M50 Tablet is inadvisable.

PregnancyPregnancyCONSULT YOUR DOCTOR

Use of Stegsita-M50 Tablet during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Stegsita-M50 Tablet while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyCAUTION

Patients with kidney impairment should use Stegsita-M50 Tablets cautiously, potentially requiring dosage modification. Severe kidney disease contraindicates Stegsita-M50 Tablet use. Physician consultation is recommended. Regular monitoring of kidney function is advised during treatment.

LiverLiverUNSAFE

Individuals with liver conditions should likely refrain from using Stegsita-M50 Tablets due to potential safety risks. Medical advice is recommended.

What if you forget to take Stegsita-M50 Tablet :

Should you forget a Stegsita-M50 Tablet dose, take it immediately. However, if your next dose is imminent, omit the missed dose and resume your usual regimen. Never take a double dose.

Facts to Know About Stegsita-M50 Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Stegsita-M50 Tablet

Stegsita-M50 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Stegsita-M50 Tablet use can lead to Vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as numbness, tingling in extremities, weakness, and balance problems), and urinary issues, along with potential cognitive changes. To mitigate these risks, annual supplemental Vitamin B12 is recommended by some researchers.
Stegsita-M50 Tablet may cause common side effects such as hypoglycemia, taste changes, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may result in vitamin B12 deficiency.
Stegsita-M50 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Stegsita-M50 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Dispose of any unused medication properly and ensure it's inaccessible to children, pets, and others.
Sitagliptin/Metformin (like Stegsita-M50) can cause lactic acidosis, a serious medical emergency resulting from excessive blood lactic acid (also known as MALA—Metformin-associated lactic acidosis). This rare side effect necessitates caution in patients with kidney disease, the elderly, or those who consume large quantities of alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin immediately and seek medical attention.
Stegsita-M50 Tablet combines sitagliptin and metformin to treat type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Stegsita-M50 Tablet may cause common side effects including hypoglycemia, altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory tract infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Stegsita-M50 Tablet is contraindicated in patients with allergies to its components or excipients, and in those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Stegsita-M50 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (like Stegsita-M50) can rarely cause lactic acidosis (MALA – Metformin-associated lactic acidosis), a serious medical emergency involving high blood lactic acid levels. This risk is increased in patients with kidney disease, the elderly, and heavy alcohol users. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If these occur, discontinue Sitagliptin/Metformin immediately and seek urgent medical attention.
Prolonged Stegsita-M50 Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Stegsita-M50 Tablet combines sitagliptin and metformin to manage type 2 diabetes in adults. This medication helps control blood sugar when used with a healthy diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. Stegsita-M50 is not suitable for individuals under 18.
Stegsita-M50 Tablet may cause common side effects such as low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects include lactic acidosis. Prolonged use may also result in vitamin B12 deficiency.
Stegsita-M50 Tablets are contraindicated in patients with hypersensitivity to any ingredient. Avoid use in patients with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Stegsita-M50 tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (like Stegsita-M50) can cause lactic acidosis, a serious medical emergency resulting from excess blood lactic acid (also called Metformin-associated lactic acidosis or MALA). This rare side effect necessitates avoiding the medication in patients with kidney disease, the elderly, or those who consume excessive alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitagliptin/Metformin and seek immediate medical attention.
Prolonged Stegsita-M50 Tablet use can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate these risks, supplemental vitamin B12 is recommended at least annually, according to some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Stegsita-M50 Tablet
154